Correlation between treatment-related lymphopenia and pathologic response in esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoradiotherapy
Wang Xiushen1,Zhang Xixi1,Xi Mian2,Bo Shanshan3
1Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008,China; 2Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060,China; 3Department of Radiation Oncology, Henan Provincial Cancer Hospital, Zhengzhou 450008,China
Abstract：Objective To investigate the relationship between treatment-related lymphopenia and pathologic complete response (pCR) to neoadjuvant chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC). Methods Clinical data of 220 ESCC patients treated with neoadjuvant CRT followed by surgery between 2002 and 2016 were retrospectively analyzed. Absolute lymphocyte count was determined before and at 1 month after neoadjuvant CRT. Treatment-related lymphopenia was graded using Common Terminology Criteria for Adverse Events (CTCAE, 4.0 version). The relationship between lymphopenia, pCR and recurrence was evaluated by chi-square test and Cox’s regression model. Results Ninety-five patients (43.2%) achieved a pCR after neoadjuvant CRT and 71 cases (32.3%) recurred postoperatively. During neoadjuvant CRT, the incidence rates of grade 0,1,2,3,and 4 lymphopenia were 1.8%,6.8%,31.4%,38.2%,and 21.8%,respectively. Patients with grade 4 lymphopenia had a significantly lower pCR rate than those with grade 0-3 lymphopenia (22.9% vs.48.8%,P=0.001). Moreover, grade 4 lymphopenia was significantly associated with a higher risk of recurrence (45.8% vs.28.5%,P=0.023). Multivariate analysis identified that primary tumor length, tumor location and radiation dose were the independent predictors for grade 4 lymphopenia during neoadjuvant CRT (P=0.013,0.001,0.002). Conclusions The incidence of grade 4 lymphopenia in ESCC patients undergoing neoadjuvant CRT is correlated with a low pCR rate and a high risk of recurrence. Lymphopenia can be used as an economic and effective predictor for pCR.
Wang Xiushen,Zhang Xixi,Xi Mian et al. Correlation between treatment-related lymphopenia and pathologic response in esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoradiotherapy[J]. Chinese Journal of Radiation Oncology, 2019, 28(4): 274-279.
[1] Bray F,Ferlay J,Soerjomataram I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.DOI:10.3322/caac.21492. [2] Chen W,Zheng R,Baade PD,et al. Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.DOI:10.3322/caac.21338. [3] Formenti SC,Demaria S.Combining radiotherapy and cancer immunotherapy:a paradigm shift[J].J Natl Cancer Inst,2013,105(4):256-265.DOI:10.1093/jnci/djs629. [4] Yovino S,Grossman SA.Severity,etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas[J].CNS Oncol,2012,1(2):149-154.DOI:10.2217/cns.12.14. [5] Tang C,Liao Z,Gomez D,et al. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes[J].Int J Radiat Oncol Biol Phys,2014,89(5):1084-1091.DOI:10.1016/j.ijrobp.2014.04.025. [6] Liu LT,Chen QY,Tang LQ,et al. The prognostic value of treatment-related lymphopenia in nasopharyngeal carcinoma patients[J].Cancer Res Treat,2018,50(1):19-29.DOI:10.4143/crt.2016.595. [7] Campian JL,Sarai G,Ye X,et al. Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer[J].Head Neck,2014,36(12):1747-1753.DOI:10.1002/hed.23535. [8] Heo J,Chun M,Noh OK,et al. Sustaining blood lymphocyte count during preoperative chemoradiotherapy as a predictive marker for pathologic complete response in locally advanced rectal cancer[J].Cancer Res Treat,2016,48(1):232-239.DOI:10.4143/crt.2014.351. [9] Mandard AM,Dalibard F,Mandard JC,et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations[J].Cancer,1994,73(11):2680-2686. [10] Sjoquist KM,Burmeister BH,Smithers BM,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis[J].Lancet Oncol,2011,12(7):681-692.DOI:10.1016/S1470-2045(11)70142-5. [11] Shapiro J,van Lanschot JJB,Hulshof MCCM,et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS):long-term results of a randomised controlled trial[J].Lancet Oncol,2015,16(9):1090-1098.DOI:10.1016/S1470-2045(15)00040-6. [12] Yang H,Liu H,Chen Y,et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010):a phase Ⅲ multicenter,randomized,open-label clinical trial[J].J Clin Oncol,2018,36(27):2796-2803.DOI:10.1200/JCO.2018.79.1483. [13] Xi M,Yang Y,Zhang L,et al. Multi-institutional analysis of recurrence and survival after neoadjuvant chemoradiotherapy of esophageal cancer:the impact of histology on recurrence patterns and outcomes[J].Ann Surg,2018,in press. DOI:10.1097/SLA.0000000000002670. [14] Scheer RV,Fakiris AJ,Johnstone PA.Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer[J].Int J Radiat Oncol Biol Phys,2011,80(4):996-1001.DOI:10.1016/j.ijrobp.2010.03.003. [15] Davuluri R,Jiang W,Fang P,et al. Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy[J].Int J Radiat Oncol Biol Phys,2017,99(1):128-135.DOI:10.1016/j.ijrobp.2017.05.037. [16] Fang P,Jiang W,Davuluri R,et al. High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer[J].Radiother Oncol,2018,128(3):584-590.DOI:10.1016/j.radonc.2018.02.025. [17] Siewert JR,Ott K.Are squamous and adenocarcinomas of the esophagus the same disease?[J].Semin Radiat Oncol,2007,17(1):38-44.DOI:10.1016/j.semradonc.2006.09.007. [18] Sun Y,Cheng S,Lu Y,et al. The clinical efficacy of consolidation chemotherapy for resectable esophageal squamous cell cancer after trimodality therapy[J].J Cancer Res Ther,2016,12(1):90-95.DOI:10.4103/0973-1482.148687. [19] Burt BM,Groth SS,Sada YH,et al. Utility of adjuvant chemotherapy after neoadjuvant chemoradiation and esophagectomy for esophageal cancer[J].Ann Surg,2017,266(2):297-304.DOI:10.1097/SLA.0000000000001954. [20] Yovino S,Kleinberg L,Grossman SA,et al. The etiology of treatment-related lymphopenia in patients with malignant gliomas:modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells[J].Cancer Invest,2013,31(2):140-144.DOI:10.3109/07357907.2012.762780. [21] Tang C,Liao Z,Gomez D,et al. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes[J].Int J Radiat Oncol Biol Phys,2014,89(5):1084-1091.DOI:10.1016/j.ijrobp.2014.04.025. [22] Shiraishi Y,Fang P,Xu C,et al. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer:A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy[J].Radiother Oncol,2018,128(1):154-160.DOI:10.1016/j.radonc.2017.11.028. [23] Besser MJ,Shapira-Frommer R,Itzhaki O,et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma:intent-to-treat analysis and efficacy after failure to prior immunotherapies[J].Clin Cancer Res,2013,19(17):4792-4800.DOI:10.1158/1078-0432.CCR-13-0380. [24] Li J,Chen QY,He J,et al. Phase Ⅰ trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma[J].Oncoimmunology,2015,4:e976507.DOI:10.4161/23723556.2014.976507.
2019, Vol. 28 
